MY142441A - Azole derivatives as inhibitors of lipases and phospholipases - Google Patents

Azole derivatives as inhibitors of lipases and phospholipases

Info

Publication number
MY142441A
MY142441A MYPI20061785A MYPI20061785A MY142441A MY 142441 A MY142441 A MY 142441A MY PI20061785 A MYPI20061785 A MY PI20061785A MY PI20061785 A MYPI20061785 A MY PI20061785A MY 142441 A MY142441 A MY 142441A
Authority
MY
Malaysia
Prior art keywords
phospholipases
lipases
inhibitors
azole derivatives
azole
Prior art date
Application number
MYPI20061785A
Other languages
English (en)
Inventor
Gerhard Dr Zoller
Stefan Dr Petry
Nobert Dr Tennagels
Hubert Dr Heuer
Guenter Dr Muerller
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY142441(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY142441A publication Critical patent/MY142441A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI20061785A 2005-04-20 2006-04-19 Azole derivatives as inhibitors of lipases and phospholipases MY142441A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005018389A DE102005018389A1 (de) 2005-04-20 2005-04-20 Azolderivate als Inhibitoren von Lipasen und Phospholipasen

Publications (1)

Publication Number Publication Date
MY142441A true MY142441A (en) 2010-11-30

Family

ID=36694158

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20061785A MY142441A (en) 2005-04-20 2006-04-19 Azole derivatives as inhibitors of lipases and phospholipases

Country Status (20)

Country Link
US (1) US8921404B2 (https=)
EP (1) EP1874741A1 (https=)
JP (1) JP2008536884A (https=)
KR (1) KR20080004501A (https=)
CN (1) CN101160293A (https=)
AR (1) AR053228A1 (https=)
AU (1) AU2006237127A1 (https=)
BR (1) BRPI0608495A2 (https=)
CA (1) CA2606301A1 (https=)
DE (1) DE102005018389A1 (https=)
IL (1) IL186635A0 (https=)
MA (1) MA29393B1 (https=)
MX (1) MX2007012732A (https=)
MY (1) MY142441A (https=)
NO (1) NO20075938L (https=)
NZ (1) NZ562694A (https=)
RU (1) RU2414458C2 (https=)
TW (1) TW200722421A (https=)
WO (1) WO2006111321A1 (https=)
ZA (1) ZA200707929B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
CN101646655A (zh) 2007-04-05 2010-02-10 塞诺菲-安万特股份有限公司 作为脂肪酶和磷脂酶抑制剂的咪唑烷甲酰胺衍生物
RU2009140760A (ru) 2007-04-05 2011-05-10 Санофи-Авентис (Fr) 5-оксоизоксазолы в качестве ингибиторов липаз и фосфолипаз
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
KR20120123325A (ko) 2009-12-15 2012-11-08 시오노기세야쿠 가부시키가이샤 혈관 내피 리파아제 저해 활성을 갖는 옥사디아졸 유도체
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2996681C (en) * 2015-08-27 2024-04-09 Auckland Uniservices Limited Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208690T3 (es) * 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
WO2003005184A2 (en) 2001-07-04 2003-01-16 Akodi S.A. Web windowed graphical user interface
JP2003033007A (ja) 2001-07-09 2003-01-31 Sanyo Electric Co Ltd チャージポンプ回路の制御方法
EP1458374A2 (en) * 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
US7217727B2 (en) * 2003-04-01 2007-05-15 Eli Lilly And Company Phospholipase inhibitors
US7595403B2 (en) * 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
CA2559105A1 (en) * 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound

Also Published As

Publication number Publication date
NZ562694A (en) 2010-05-28
ZA200707929B (en) 2008-12-31
TW200722421A (en) 2007-06-16
BRPI0608495A2 (pt) 2010-01-05
NO20075938L (no) 2007-11-19
CA2606301A1 (en) 2006-10-26
WO2006111321A1 (de) 2006-10-26
US20080090867A1 (en) 2008-04-17
JP2008536884A (ja) 2008-09-11
AR053228A1 (es) 2007-04-25
CN101160293A (zh) 2008-04-09
IL186635A0 (en) 2008-01-20
MX2007012732A (es) 2008-03-14
KR20080004501A (ko) 2008-01-09
AU2006237127A1 (en) 2006-10-26
MA29393B1 (fr) 2008-04-01
DE102005018389A1 (de) 2006-10-26
RU2007142657A (ru) 2009-05-27
EP1874741A1 (de) 2008-01-09
US8921404B2 (en) 2014-12-30
RU2414458C2 (ru) 2011-03-20

Similar Documents

Publication Publication Date Title
MY142441A (en) Azole derivatives as inhibitors of lipases and phospholipases
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
TW200626558A (en) Indazolone derivatives
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
MXPA02005844A (es) Inhibidores de cinasas de proteina.
MX2007005408A (es) Compuestos de aminoquinazolinas.
TW200833324A (en) Sulfonamide derivatives
JO2585B1 (en) Benzocoinazoline derivatives
MY138941A (en) Aryl-pyridine derivatives
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
TW200628158A (en) Promoting neochondrogenesis using kinase inhibitors
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
TW200716628A (en) Novel compounds
MX2009010485A (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas.
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
TW200616976A (en) Pyrimidine derivatives
GB0314967D0 (en) Piperazine derivatives
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2009003169A (es) Derivados de sulfonamida.
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
TW200612964A (en) Methods for preparing p2x7 inhibitors